# A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

> **NCT06317285** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 158 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** GSK3915393
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06317285
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-04-04
- **Primary completion:** 2025-10-01
- **Final completion:** 2025-10-01
- **Target enrollment:** 158 (ACTUAL)
- **Why stopped:** The study met futility criteria at pre-planned interim analysis, showing no clinical efficacy of the investigational drug. Based on the lack of efficacy at the interim data review, the sponsor decided to terminate the study.
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06317285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06317285, "A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06317285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*